A legislative committee has approved the use of medical marijuana in Connecticut to treat chronic neuropathic pain associated with degenerative spinal disorders.
The Regulations Review Committee of the General Assembly approved it Wednesday, according to the state Department of Consumer Protection.
The Committee also voted to update regulations to reschedule the medication Epidiolex, or cannabidol, as a Schedule V medication. It is an oral solution used for some rare, severe types of seizure disorders.
The state Department of Consumer Protection will submit the regulations to the Secretary of the State's Office, who will post the regulations online.
As of Nov. 8, there are 29,543 patients in Connecticut’s medical marijuana program, 1,000 certifying physicians, 31 conditions approved for adults and eight for patients under 18.
